These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25013909)

  • 21. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
    Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
    Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine.
    Thomas MC; Greten TF; Pardoll DM; Jaffee EM
    Hum Gene Ther; 1998 Apr; 9(6):835-43. PubMed ID: 9581906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Gruber TA; Skelton DC; Kohn DB
    J Immunol; 2002 Jan; 168(1):73-80. PubMed ID: 11751948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
    Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
    Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
    J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and synergistic control of Ph(+) ALL by a DNA vaccine and 6-mercaptopurine.
    Köchling J; Rott Y; Arndt S; Marschke C; Schmidt M; Wittig B; Kalies K; Westermann J; Henze G
    Vaccine; 2012 Sep; 30(41):5949-55. PubMed ID: 22841975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.
    Büeler H; Mulligan RC
    Mol Med; 1996 Sep; 2(5):545-55. PubMed ID: 8898371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-enhancing effect of nano-DNA vaccine encoding a gene of the prME protein of Japanese encephalitis virus and BALB/c mouse granulocyte-macrophage colony-stimulating factor.
    Zhai Y; Zhou Y; Li X; Feng G
    Mol Med Rep; 2015 Jul; 12(1):199-209. PubMed ID: 25738258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
    McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
    J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells.
    Schneeberger A; Lührs P; Kutil R; Steinlein P; Schild H; Schmidt W; Stingl G
    J Immunol; 2003 Nov; 171(10):5180-7. PubMed ID: 14607918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
    Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
    Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals.
    Herrero MJ; Botella R; Dasí F; Algás R; Sánchez M; Aliño SF
    Ann N Y Acad Sci; 2006 Dec; 1091():412-24. PubMed ID: 17341632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.